RxDoctor Payments Data

Niranjan Selvarajah, MD

Family Medicine · New Hartford, NYNPI 1548256399

Payments from drug & device makers

$12,610in general payments, 2019–2025

Across 705 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • AstraZeneca$2K
  • Pfizer$947
  • Lilly USA, LLC$934
  • Amgen$655
  • plus $4K from 34 others

What the payments were for

  • Food & beverage$12,610100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,610 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$160,272
Medicare patients
322
Services billed
6,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$67,322
JardianceEmpagliflozin60$61,881
FarxigaDapagliflozin Propanediol46$40,019
EliquisApixaban47$36,780
JanuviaSitagliptin Phosphate36$25,513
TrulicityDulaglutide17$14,089
MounjaroTirzepatide12$14,083
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,650
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$10,450
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,066
Insulin Lispro Kwikpen U-100Insulin Lispro23$2,907
Metoprolol Succinate133$2,647
Atorvastatin Calcium204$2,498
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,012
SynthroidLevothyroxine Sodium19$1,631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,924$67,32259 claims
Boehringer IngelheimJardiance$491$61,88160 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,856$50,46957 claims
PfizerEliquis$947$36,78047 claims
Lilly USA, LLCTrulicity, Mounjaro$934$28,17229 claims
MerckJanuvia$405$25,51336 claims
GSKTrelegy Ellipta$439$11,65011 claims
AbbVieSynthroid$2,206$1,63119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in New Hartford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →